News

Biocon Biologics expands diabetes portfolio with FDA approval for Kirsty
Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...
Capital Market on MSN2d
Biocon arm gets USFDA approval for insulin, Kirsty
Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...
The Pharma Letter2d
FDA approves Biocon BLA for Kirsty
The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...
Should you buy Biocon shares as USFDA gives approval to diabetes drug?
Biocon share price today: Shares of Biocon witnessed a 3 per cent gain, logging an intraday high of ₹405.9 on Wednesday after ...
Medical Dialogues2d
Biocon Biologics expands biosimilar insulin portfolio with USFDA nod of Kirsty
Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...
Rediff Money2d
Biocon's Kirsty: USFDA Approval for Diabetes Drug
Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...
Stocktwits on MSN2d
Buy Biocon, Zydus Life For Short-Term Gains, Says SEBI RA Vinayak Gautam After Fresh Regulatory Approvals
Biocon and Zydus Lifesciences are in the spotlight with fresh regulatory approvals fueling bullish analyst sentiment and renewed retail interest. Biocon shares rose 2% on Wednesday after its ...
Stocktwits on MSN2d
Trading Radar For July 16: ICICI Lombard, Dixon, Biocon, Zydus And HDFC Life Are Among The Stocks To Watch
Indian equity markets snapped a four-session losing streak to end in positive territory on Tuesday, driven by gains in auto ...
Trade Brains on MSN2d
Pharma stock jumps 4% after receiving USFDA approval for diabetes treatment drug
The shares of the prominent pharmaceutical company gained up to 4 percent in today's trading session after the company ...
Biocon Biologics gets USFDA nod for diabetes medication
Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It is a rapid-acting insulin analog. The medication will be ...
Biocon Biologics Expands Diabetes Portfolio With FDA Approval Of Kirstytm, The First And Only Interchangeable Rapid-Acting Insulin Aspart In The United States
BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...
EquityBulls1d
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™
Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...